Rixol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rixol

Property Description
Active ingredient Risperidone
Form Tablets, Oral Solution, Injectable Suspension
Pharmacological class Atypical Antipsychotic (Second-Generation Antipsychotic)
Common use Promoting neurological stability
Origin Synthetic organic compound

Rixol is the trade name for a psychotropic agent whose active ingredient is the chemical substance Risperidone. This medication is formally categorized as an Atypical Antipsychotic. Its structural foundation places it within the chemical class of benzisoxazole derivatives.


Rixol: Classification and Core Identity

Rixol's identity is rooted in its composition as a single active ingredient product containing Risperidone, a synthetic organic compound belonging to the Second-Generation Antipsychotic (SGA) pharmacological class. Risperidone is extensively used to manage symptoms related to severe mental disturbances through its dual action on key brain messengers. Clinically, this approach is widely recognized for its efficacy in achieving stabilization. This classification signifies that its effect in the brain involves a differentiated interaction with multiple neuroreceptors, particularly modulating the activity of neurotransmitters like dopamine and serotonin. This mechanism supports individuals requiring management of conditions characterized by thought disorganization.


Composition, Forms, and General Purpose

The active compound, Risperidone, is prepared in several distinct pharmaceutical preparations. These include oral forms, such as film-coated tablets, a liquid Oral Solution, and quick-dissolving Orally Disintegrating Tablets (ODT). The availability of the ODT form provides a unique administrative feature for patients who may have difficulty swallowing. Furthermore, it is available in Long-acting injectable suspensions for parenteral delivery, which allows for scheduled administration over extended periods. The overall purpose of Rixol is to promote neurological stability by modulating excessive or disorganized signaling pathways, thereby supporting the management of severe disturbances in thought and perception.

Regulatory References

  1. MedlinePlus Drug Information on Risperidone

What side effects are possible with Rixol?

The official safety documentation for Rixol (Ambroxol Hydrochloride, a mucolytic agent) outlines its adverse reaction profile, contraindications, and specific warnings for certain populations. The drug is generally considered well-tolerated.

Serious and Clinically Significant Adverse Reactions

  • Hypersensitivity Reactions: While rare, severe allergic responses such as skin eruption, urticaria, or angioneurotic edema may occur. The medication is strictly contraindicated in patients with a history of hypersensitivity to any of its components.
  • Gastrointestinal Caution: Rixol should be used with caution in individuals with gastric or duodenal ulceration. Prolonged use may rarely be associated with side effects such as epigastric pain or a feeling of stomach overfill.

Common Adverse Reactions (System-Organ Classes)

Adverse reactions are predominantly mild and affect the gastrointestinal system. The safety classification notes that Rixol is well-tolerated in most patients. The frequency of most adverse events is generally considered uncommon or rare. Reported side effects include:

  • Nausea and vomiting
  • Upset stomach / dyspepsia

Population-Specific Safety Considerations

Population Safety Note (As per official documentation)
Pregnancy Contraindicated during the first trimester due to a lack of complete safety data, although fetal toxicity studies have shown no harmful effects.
Gastric/Duodenal Ulcer Use with caution.

Safety-Related Restrictions

Rixol should not be taken simultaneously with antitussive medications (e.g., Codeine). This restriction is in place because the liquefying effect of Rixol on phlegm, combined with the cough-suppressing action of antitussives, may impair the ability to properly clear the respiratory tract. Official documents advise that the safety of Rixol during lactation has not yet been established. The drug can be prescribed to patients with diabetes mellitus.

Overdose and Emergency Response

Rixol Overdose and When to Seek Help

Official regulatory information regarding Rixol overdose is structured to guide immediate emergency response and management. The documented overdose presentations frequently involve the central nervous system and cardiovascular system.

Overdose Scope

Element Official Regulatory Content
Documented overdose presentations: Central Nervous System (CNS) depression (e.g., somnolence), Tachycardia (fast heartbeat), Hypotension (low blood pressure), and Extrapyramidal Symptoms.
Physiological systems affected (as stated in label): Neurological and Cardiovascular.
Dose-related or exposure-related factors: Severity of clinical manifestations may increase with the total dose ingested.
Population-specific overdose notes (if applicable): Children and the elderly may require urgent assessment due to potential increased sensitivity to CNS and cardiac effects.
Emergency-response statements (as written in official documents): "Get medical help or contact a Poison Control Center right away."
When immediate medical help is required (label-derived phrasing only): "Quick medical attention is critical... even if you do not notice any signs or symptoms."

Resulting Overdose Structure

Official overdose statements:

  • The documented serious outcomes include respiratory failure, seizures, coma, and significant cardiac instability, such as QTc prolongation.
  • There is no specific pharmacological antidote available or listed for Rixol overdose; management is primarily symptomatic and supportive.
  • Continuous observation and monitoring, including repeated ECGs and laboratory tests, are required until the patient is clinically stable.

Connection to the overall overdose profile (2–4 sentences):

The regulatory documents define the overdose profile by listing the specific documented signs of toxicity, which establish the immediate risks, such as severe CNS or cardiac changes. This profile mandates the Mandatory Emergency Actions, providing the explicit, non-optional instruction for users to seek urgent professional medical attention. The remaining official statements guide the subsequent supportive clinical care and required monitoring procedures.

Therapeutic Uses of Rixol

What Rixol Treats: Main Uses and Benefits

Rixol is applied across domains where additional symptomatic support is needed, and is relevant in conditions presenting with systemic or localized discomfort. It is considered relevant for supportive symptom management in specific blood disorders, including myelofibrosis and polycythemia vera.

The medication is commonly used when symptoms intensify, assisting in the management of symptoms that create noticeable physiological strain, such as recurrent fevers and night sweats, and symptoms related to physical discomfort, such as persistent itching. This use helps ease symptoms that may become intense or disruptive.

“It supports the patient during difficult episodes by easing distress and assists with maintaining a sense of stability when symptoms are more noticeable.”

Key Symptom Domains

Rixol helps address symptom clusters that may become intense or disruptive, offering symptomatic relief that helps patients cope more steadily. It is relevant for easing symptoms linked to organ-specific functional stress, such as the physical discomfort associated with an enlarged spleen (splenomegaly). This supportive relief is commonly used during phases when symptoms become more noticeable.


Quick Fact: Relief for Systemic Discomfort and Inflammation-Related Itching


Regulatory References

  1. European Medicines Agency (EMA) public assessment report

Eligibility and Restrictions for Use

Rixol (Risperidone) eligibility is strictly defined by regulatory authorities and is not universal. The medicine is contraindicated and must not be used by patients with a known hypersensitivity to the drug substance or its excipients. Crucially, the drug is also not approved for use in elderly patients with dementia-related psychosis, as use in this population is associated with an increased risk of stroke and death, a warning mandated by regulatory agencies.

Eligibility is determined by precise age rules. For instance, safety and effectiveness are not established for schizophrenia in children under 13 years of age, or for bipolar mania in children under 10 years of age. Use in children under five years old is not established for any approved indication.

Furthermore, use is restricted and requires caution in populations with impaired organ function. Patients with severe renal or hepatic impairment are required to start treatment at a lower dose due to their reduced ability to process the medicine. Use also requires caution for patients with a history of seizures or specific cardiovascular conditions. For pregnant or breastfeeding women, use is highly conditional, with the drug being not recommended during lactation due to its presence in breast milk.

What should I know about interactions with other medicines?

Rixol Interactions with other medicines and products

It is essential to inform your doctor or pharmacist of all medicines and supplements you are currently taking, as Rixol may interact with many substances, potentially increasing the risk of adverse effects, including the serious condition known as serotonin syndrome.

Do not take Rixol with:

  • Monoamine Oxidase Inhibitors (MAOIs): Combining Rixol with MAOIs (e.g., phenelzine, tranylcypromine, linezolid) is contraindicated due to the significantly increased risk of severe, potentially fatal, serotonin syndrome. A washout period is required when switching between these medications.

Caution is advised with:

Category Examples of Interacting Medicines Potential Risk/Effect
Other Serotonergic Drugs Triptans (for migraine), other antidepressants (SSRIs, SNRIs, TCAs), St. John's Wort, tramadol, buspirone, fentanyl. Increased risk of serotonin syndrome (symptoms include agitation, confusion, rapid heart rate, high fever).
Drugs Affecting Bleeding Warfarin, aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. Increased risk of bleeding (e.g., gastrointestinal hemorrhage) due to Rixol's potential effect on platelet function.
CYP Enzyme Inhibitors/Inducers Certain antifungals (e.g., fluconazole), some anti-HIV drugs, and some anticonvulsants (e.g., phenytoin, carbamazepine). These may alter the concentration of Rixol in the blood, potentially leading to reduced efficacy or increased side effects.

Food/Beverage Interactions

Consumption of alcohol while taking Rixol is not recommended, as it can intensify the drug's effects on the central nervous system, leading to increased drowsiness or impaired judgment. Grapefruit juice may also affect the metabolism of certain medications and should be discussed with your healthcare provider.

Mechanism of Action

Rixol is a compound containing Ambroxol, a secretolytic agent that acts primarily on the respiratory mucosa and alveolar cells. Its mechanism involves three distinct pathways.

First, Ambroxol functions as a secretagogue, stimulating the serous cells of the bronchial glands to increase the production and secretion of a less viscous mucus component. Simultaneously, it exerts a mucolytic action by depolymerizing and cleaving mucopolysaccharide fibers within the endogenous mucus, which decreases its overall viscoelasticity.

Second, Rixol accumulates in the lamellar bodies (secretory lysosomes) of alveolar type II pneumocytes. Acting as a weak base, it induces a pH neutralization within these acidic stores, triggering an intracellular Ca^2+ release. This Ca^2+-dependent signal mediates the exocytosis and subsequent secretion of pulmonary surfactant (a phospholipid mixture) into the alveolar lumen, thereby contributing to the reduction of alveolar surface tension.

Third, Rixol exhibits anti-inflammatory properties through the non-competitive inhibition of cellular cytokine production and the modulation of the arachidonic acid cascade, limiting the formation of associated metabolites. The net system-level physiological consequence of these combined actions is a reduction in mucus viscosity, an increase in bronchial secretions, and a modulation of airway reactivity.

Dosage and Administration Information

Rixol is administered through two primary approaches: oral ingestion and parenteral injection. Oral forms include tablets, an oral solution, and Orally Disintegrating Tablets (ODT). The long-acting injectable suspensions are administered via deep intramuscular (IM) or subcutaneous (SubQ) injection only by a healthcare professional.

Official Dosing and Frequency Patterns

The usage protocol mandates a principle of slow dose titration. For adults, the initial oral dose is typically 2 mg per day, taken once or twice daily. The dose is then gradually increased to reach a target maintenance range, often between 4 mg and 8 mg per day. The official maximum daily oral dose is 16 mg. Oral forms can be taken independently of meals, with or without food.

Long-acting injectable forms follow an intermittent schedule, administered every two weeks or up to once every two months, depending on the specific formulation. If a patient is starting the two-week IM injection, oral medication is typically administered concurrently for the first three weeks to ensure proper compound levels are established.

Specific Administration Instructions

The official usage guidelines specify modifications for certain patient populations. For older adults and individuals with renal or hepatic impairment, the starting dose must be reduced, commonly to 0.5 mg twice daily, and the subsequent titration must be performed at a significantly slower pace. The oral solution must not be mixed with cola or tea, and Orally Disintegrating Tablets (ODT) should be placed on the tongue without being split or chewed.

Recent Clinical Evidence

Research evidence / Overview of studies for Rixol

Evidence for use in Type 2 Diabetes Mellitus

Research has primarily focused on how Rixol was evaluated in conditions characterized by Type 2 Diabetes Mellitus. Randomized Controlled Trials (RCTs) were used in research exploring this area. These studies monitored outcomes related to systemic or functional imbalance, such as changes in long-term blood sugar markers like glycated hemoglobin (HbA1c), as well as measurements of body weight.

Findings describe patterns observed in the studies where differences in mean HbA1c values were observed in participants receiving Rixol compared to those receiving placebo or other comparators after various study periods. Research highlights changes measured in body weight, with some trials reporting variations in measurements between the groups. Comparative evidence is lacking for direct, head-to-head comparisons against every currently available medication for Type 2 Diabetes Mellitus.


Evidence for use in Cardiovascular Risk Reduction

Large, long-term Cardiovascular Outcomes Trials (CVOTs) were applied in studies examining the risk of serious episodic or acute changes related to the heart and blood vessels. Researchers monitored a composite outcome known as Major Adverse Cardiovascular Events (MACE), including cardiovascular death and non-fatal heart attack. The research primarily recorded patterns related to the number of MACE events that were observed in the Rixol treatment groups compared to the control groups. These findings describe patterns observed in the studies that generally focused on participants who were at high baseline risk for cardiovascular events.


Evidence for use in Chronic Kidney Disease

Studies focusing on conditions marked by functional limitations related to the kidneys evaluated Rixol. Research examined outcomes related to systemic or functional imbalance by measuring changes in markers like estimated Glomerular Filtration Rate (eGFR) and the urine albumin-to-creatinine ratio (UACR). Studies reported how symptoms evolved in the observed populations, describing patterns in the measured rate of eGFR decline that were recorded in the Rixol group when compared to the control group. Data for certain groups remain insufficient, particularly for people with non-diabetic kidney disease or those in the most advanced stages of CKD.


What is Still Uncertain About Rixol

Evidence is limited regarding the long-term patterns of change after many years of use. Long-term effects are not fully established beyond the specific trial durations. Data for certain groups remain insufficient when considering the youngest patient groups or specific complex combinations of other medical conditions. Overall, research is ongoing to provide more context and clarity.

Frequently Asked Questions (FAQ)

Common questions about Rixol (FAQ)


Q: Can Rixol be taken long-term?

Official information states that physicians who prescribe Rixol for extended periods should periodically re-evaluate the risks and benefits for the individual patient. This consideration is important due to the risk of developing Tardive Dyskinesia (TD), a condition causing involuntary movements, which may increase with the duration of treatment.


Q: Does Rixol cause drowsiness or make you tired?

Yes, regulatory documents report that drowsiness, sedation, and tiredness are common side effects of Rixol. The official label suggests using caution when performing tasks that require mental alertness, such as driving or operating heavy machinery, until the individual understands how the medication affects them.


Q: Is it safe to take Rixol with common cold medicine?

The product information states that caution should be exercised when Rixol is combined with other medicines that cause sleepiness, including some common cold or allergy medications. Taking them together may increase side effects like dizziness and excessive drowsiness, potentially impairing alertness and coordination.


Q: Can Rixol affect my sleep?

Official adverse reaction reports indicate that insomnia (trouble falling or staying asleep) has been noted as a common side effect of Rixol in clinical trials. Any persistent or concerning changes to sleep should be reviewed with the prescribing healthcare provider.


Q: Do older adults need a different dose of Rixol?

Yes, official regulatory documents state that for older adults and individuals with severe kidney or liver problems, the starting dose must be reduced. The process of slowly increasing the dose (titration) must also be performed at a significantly slower pace, which is required due to their reduced ability to process the medication.


Q: Are there any major diet restrictions when taking Rixol?

While Rixol can typically be taken with or without food, individuals should consult their healthcare provider regarding the consumption of grapefruit juice, as it may affect how the medication is processed by the body. Consumption of alcohol is generally not recommended when taking Rixol.


Q: What should I do if I think I'm having an allergic reaction to Rixol?

The regulatory information indicates that if signs of a severe allergic reaction (such as difficulty breathing, hives, or swelling of the face, lips, tongue, or throat) occur, immediate emergency medical attention should be sought.


Q: Can Rixol be taken with supplements like vitamins or herbal remedies?

It is important for individuals to disclose all supplements, vitamins, and herbal remedies to their healthcare provider. Caution is advised with herbal remedies like St. John's Wort, which can potentially reduce the effectiveness of Rixol, and supplements that may increase drowsiness.


Q: Can Rixol cause changes in mood or behavior?

Official documents list side effects like anxiety, agitation, and restlessness (akathisia) as common reactions. Since Rixol works by modulating brain messengers, patients are typically monitored for any significant or persistent changes in mood, thought patterns, or behavior during treatment.


Q: What happens if Rixol is stopped suddenly?

Abrupt discontinuation of Rixol is not recommended. The medication should only be stopped under the supervision of a healthcare professional to avoid the return of symptoms or potential withdrawal-like symptoms.


Q: Is it normal to feel a bit dizzy when starting Rixol?

Yes, feeling dizzy is a commonly reported side effect, especially during the initial stages of treatment. This dizziness can sometimes be related to a temporary drop in blood pressure when changing position, known as orthostatic hypotension.


Q: Are the side effects of Rixol generally mild?

Official safety data indicates Rixol is generally well-tolerated by most patients, and adverse reactions are predominantly mild. However, serious side effects, such as rare allergic reactions or movement disorders, can occur. These events are clinically significant and require prompt medical review.


Q: What happens if I miss a dose of Rixol?

Official guidance for a missed oral dose typically involves taking the dose as soon as it is remembered unless it is nearly time for the next scheduled dose. Specific instructions on how to handle missed doses are detailed in the product information and should be followed precisely.


Q: Can Rixol affect blood pressure readings?

Yes, Rixol may cause low blood pressure (hypotension), particularly when standing up (orthostatic hypotension), which can lead to dizziness or fainting. Monitoring by a healthcare provider may be necessary for individuals with pre-existing heart or blood vessel conditions.


Q: What should I avoid eating or drinking while on Rixol?

Consumption of alcohol is generally not recommended as it can intensify effects such as drowsiness. Individuals should consult a doctor regarding the consumption of grapefruit juice, as it can potentially alter the blood concentration of Rixol.


Q: Is Rixol considered a high-risk medication?

Rixol is categorized as an atypical antipsychotic and carries serious warnings mandated by regulatory agencies, including an increased risk of stroke and death when used in elderly patients with dementia-related psychosis. Prescribing Rixol involves a careful risk-benefit assessment performed by a healthcare professional.


Q: How common are serious side effects with Rixol?

While most common side effects are mild, serious reactions like severe allergic responses, blood disorders, and movement disorders are typically considered uncommon or rare. Despite their rarity, these events are clinically significant and warrant prompt medical review.


Q: Can Rixol be used in children (general question)?

Use in children is limited by regulatory age rules for specific conditions. Safety and effectiveness are not established for schizophrenia in children younger than 13 years of age, or for bipolar mania in children younger than 10 years of age. For children under five years old, use is not established for any approved purpose.


Q: Are there any specific laboratory tests required when taking Rixol?

Periodic monitoring, particularly during the initial months of treatment, is often required due to the risk of metabolic changes. Laboratory tests frequently involve checking fasting blood glucose levels, lipid panel (cholesterol), and Complete Blood Count (CBC).

How should Rixol be stored and disposed of?

How to Store and Dispose of Rixol?

The official storage conditions for Rixol are form-specific. Tablets and Oral Solution must be stored at 20 C to 25 C (68 F to 77 F), with excursions up to 30 C. The Long-Acting Injectable Suspension kit, however, requires refrigerated storage between 2 C and 8 C (36 F to 46 F).

All forms must be kept in the original container and be protected from light and moisture. The Oral Solution bottle, once opened, must be discarded after 3 months. Do not freeze the oral solution.

All Rixol forms must be stored out of the sight and reach of children.

To dispose of unused or expired product, use an authorized drug take-back program or follow local requirements. Do not flush Rixol down a toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rixol found in:

A-Z Index: